Mesoblast Stock Today
| MESO Stock | USD 11.58 0.11 0.94% |
Performance14 of 100
| Odds Of DistressLess than 12
|
Mesoblast is selling at 11.58 as of the 30th of November 2024; that is 0.94 percent decrease since the beginning of the trading day. The stock's open price was 11.69. Mesoblast has less than a 12 % chance of experiencing some financial distress in the next two years of operation and had a good performance during the last 90 days. Equity ratings for Mesoblast are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 31st of October 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 13th of November 2015 | Category Healthcare | Classification Health Care |
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia. Mesoblast operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 114.18 M outstanding shares of which 1.68 M shares are now shorted by private and institutional investors with about 6.69 trading days to cover. More on Mesoblast
Moving together with Mesoblast Stock
| 0.81 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.77 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.86 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
Moving against Mesoblast Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Mesoblast Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMesoblast can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Mesoblast's financial leverage. It provides some insight into what part of Mesoblast's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mesoblast (MESO) is traded on NASDAQ Exchange in USA. It is located in 55 Collins Street, Melbourne, VIC, Australia, 3000 and employs 73 people. Mesoblast is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.14 B. Mesoblast conducts business under Biotechnology sector and is part of Health Care industry. The entity has 114.18 M outstanding shares of which 1.68 M shares are now shorted by private and institutional investors with about 6.69 trading days to cover.
Mesoblast currently holds about 85.5 M in cash with (48.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.62.
Check Mesoblast Probability Of Bankruptcy
Ownership AllocationMesoblast maintains a total of 114.18 Million outstanding shares. Roughly 98.55 % of Mesoblast outstanding shares are held by general public with 0.072 pct. owned by insiders and only 1.38 % by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Mesoblast Ownership Details
Mesoblast Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Citadel Advisors Llc | 2024-09-30 | 40 K | |
| Lpl Financial Corp | 2024-09-30 | 36.1 K | |
| Xy Capital Ltd | 2024-09-30 | 29.9 K | |
| Two Sigma Investments Llc | 2024-09-30 | 20.4 K | |
| Bank Of America Corp | 2024-06-30 | 20.1 K | |
| Chapin Davis Inc | 2024-09-30 | 15 K | |
| Rathbone Brothers Plc | 2024-06-30 | 14 K | |
| Millennium Management Llc | 2024-06-30 | 13.5 K | |
| Pine Valley Investments Ltd Liability Co | 2024-06-30 | 11.7 K | |
| Group One Trading, Lp | 2024-06-30 | 227.8 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 167.2 K |
Mesoblast Historical Income Statement
Mesoblast Stock Against Markets
Mesoblast Corporate Management
| Roger BA | Head Disorders | Profile | |
| Fiona See | Senior Research | Profile | |
| MS MBA | Chief Officer | Profile | |
| BSc LLB | Gen Exec | Profile | |
| FACP FACRA | CEO, Founder | Profile | |
| LLB BCom | Joint Secretary | Profile | |
| Justin BS | Head Manufacturing | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share 0.06 | Quarterly Revenue Growth (0.41) | Return On Assets (0.05) | Return On Equity (0.18) |
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.